The FDA approves biosimilar chemo infection risk treatment Filkri for cancer patients, expanding granulocyte colony-stimulating factor options.
If the biological developed by Novartis to imitate Amgen's Neupogen is approved by the FDA, it'd open floodgates as other biosimilars find their way to the FDA's doorsteps. The cheaper alternatives ...
The U.S. Food and Drug Administration (FDA) has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), to ...
The Food and Drug Administration (FDA) has approved Filkri ® (filgrastim-laha), a biosimilar to Neupogen ® (filgrastim). Filkri, a leukocyte growth factor, is approved to: ...
FDA’s Oncologic Drugs Advisory Committee will meet January 7 to discuss Sandoz’s biologics license application for EP2006, a biosimilar version of Amgen’s top-selling Neupogen (filgrastim) and the ...
The first wave of biosimilars began lapping at U.S. shores five years ago when the FDA approved Sandoz Inc.’s Zarxio on March 6, 2015, giving it a label identical to that of its reference biologic, ...
An Indiana University Melvin and Bren Simon Cancer Center researcher played a role in the recent Food and Drug Administration approval of a drug to treat people exposed to potentially lethal doses of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results